Regeneron Pharmaceuticals Inc (REGN)
963.63
-6.34
(-0.65%)
USD |
NASDAQ |
May 08, 10:48
Regeneron Pharmaceuticals Enterprise Value: 98.34B for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | 98.34B |
| May 06, 2024 | 97.09B |
| May 03, 2024 | 96.91B |
| May 02, 2024 | 94.77B |
| May 01, 2024 | 91.01B |
| April 30, 2024 | 89.60B |
| April 29, 2024 | 89.80B |
| April 26, 2024 | 88.78B |
| April 25, 2024 | 89.60B |
| April 24, 2024 | 91.35B |
| April 23, 2024 | 91.44B |
| April 22, 2024 | 90.65B |
| April 19, 2024 | 90.28B |
| April 18, 2024 | 89.97B |
| April 17, 2024 | 90.76B |
| April 16, 2024 | 89.99B |
| April 15, 2024 | 90.47B |
| April 12, 2024 | 91.15B |
| April 11, 2024 | 92.87B |
| April 10, 2024 | 94.62B |
| April 09, 2024 | 95.47B |
| April 08, 2024 | 94.87B |
| April 05, 2024 | 95.34B |
| April 04, 2024 | 94.71B |
| April 03, 2024 | 96.24B |
| Date | Value |
|---|---|
| April 02, 2024 | 96.66B |
| April 01, 2024 | 98.27B |
| March 31, 2024 | 97.52B |
| March 28, 2024 | 96.78B |
| March 27, 2024 | 97.20B |
| March 26, 2024 | 96.90B |
| March 25, 2024 | 96.63B |
| March 22, 2024 | 97.30B |
| March 21, 2024 | 97.39B |
| March 20, 2024 | 97.27B |
| March 19, 2024 | 96.91B |
| March 18, 2024 | 96.50B |
| March 15, 2024 | 97.00B |
| March 14, 2024 | 96.40B |
| March 13, 2024 | 97.11B |
| March 12, 2024 | 97.67B |
| March 11, 2024 | 97.00B |
| March 08, 2024 | 97.48B |
| March 07, 2024 | 97.97B |
| March 06, 2024 | 97.84B |
| March 05, 2024 | 97.08B |
| March 04, 2024 | 97.74B |
| March 01, 2024 | 99.01B |
| February 29, 2024 | 97.18B |
| February 28, 2024 | 99.54B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
27.20B
Minimum
Oct 02 2019
100.17B
Maximum
Feb 27 2024
62.43B
Average
63.06B
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals Inc | 95.81B |
| Amgen Inc | 215.46B |
| Eli Lilly and Co | 762.91B |
| Moderna Inc | 37.87B |
| Gilead Sciences Inc | 76.87B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 722.00M |
| Revenue (Quarterly) | 3.145B |
| Total Expenses (Quarterly) | 2.386B |
| EPS Diluted (Quarterly) | 6.27 |
| Gross Profit Margin (Quarterly) | 86.21% |
| Profit Margin (Quarterly) | 22.96% |
| Earnings Yield | 3.51% |
| Operating Earnings Yield | 3.63% |
| Normalized Earnings Yield | 3.803 |